However, a study of 178 Asian patients with advanced melanoma (26% with mucosal melanoma) receiving immune checkpoint inhibitors showed that NRAS mutations, TP53 mutations and NF2 deletions are associated with resistance to checkpoint inhibitors, with MYC and RPS6KB1 amplifications more frequent in patients responding to treatment with immune checkpoint inhibitors (59). The gene discussed is NRAS; the disease is melanoma.